http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
심창구,김대덕,정인환,김현수,유무영,Shim, Chang-Koo,Kim, Dae-Duk,Jung, In-Whoan,Kim, Hyun-Su,Yoon, Moo-Yung 한국약제학회 1986 Journal of Pharmaceutical Investigation Vol.16 No.3
Time-concentration curves of recombinant human interferon alpha$(rIFN-{\alpha}A)$ in the skin and serum of nude mice or rats were studied after topical application of IFN ointment. IFN appeared in the skin and serum in less than 30 minutes and lasted for more than 10-12 hours at high concentration level after the application to nude mice at a dose of $9.0{\times}10^5\;IU/g$ mouse. But in the rats, IFN was not detected in the serum even 7 hours after the application at a dose of $6.0{\times}10^5\;IU/g$ rat. Topical application of IFN might be useful for the topical and systemic treatment if the human skin resembles that of nude mouse in respect to transport characteristics.
심창구,김대덕,김현수,정인환,유무영 ( Chang Koo Shim,Dae Duk Kim,Hyun Su Kim,In Whoan Jung,Moo Young Yoo ) 생화학분자생물학회 1987 BMB Reports Vol.20 No.2
Pharmacokinetic behavior of recombinant human interferon alpha (rIFN- α A) was studied in the rat. Serum concentrations of rIFN- α A after intravenous administration could be explained by two - compartment open model. Pharmacokinetic parameters of rIFN- α A administered intravenously at two different doses (9.0 × 10^6 and 3.6 × 10^7 IU/Kg) were calculated by fitting the observed data to the nonlinear least square program. There were no significant differences in pharmacokinetic parameters such as systemic clearance (CLs), apparent distribution volume at steady state (Vd_(ss)), biological half life (t_½) etc. between the two doses. There were also no significant differences between pharmacokinetic parameters of this rIFN- α A and those of Namalva IFN- α which were reported previously by us. rIFN- α A aministered intraveneously had a small distribution volume, which indicates its poor distribution to peripheral or poorly-perfused organs. Renal excretion which might be a sum of filtration, secretion, reabsorption or catabolism in the kidney didn`t show any saturation phenomena in the serum concentration range studied (1 × 10³ - 5 × 10⁴ IU/㎖). Renal clearance accounted less than 0.1% of systemic clearance of rIFN- α A.
피막법에 의한 경구투여용 제어방출제제의 개발-III-테오필린함유 제어방출제제의 제조 및 사람의 타액중 농도로부터의 평가-
심창구,김종국,이민화,김신근,Shim, Chang-Koo,Kim, Chong-Kook,Lee, Min-Hwa,Kim, Shin-Keun 한국약제학회 1992 Journal of Pharmaceutical Investigation Vol.22 No.3
In order to develop a controlled-release oral drug delivery system (DDS) of theophylline (TP), microporous membrane-coated tablets were prepared and evaluated in vitro and in vivo. Rapidly water-soluble core tablets of TP (300 mg) were prepared by wet granulation and compression technique, Then the core tablets were spray-coated with polyvinylchloride (PVC) in which micronized sucrose particles were dispersed. Effect of formula compositions of coating suspensions on the pharmaceutical characteristics such as membrane strength and dissolution was investigated in vitro. The membranes remained unbroken in pH 1.2 buffer at $37^{\circ}C$ at least for 2 hours after the disintergration test. TP was released from the coated-released tablets at a zero-order rate over 8 hours. The release at pH 1.2 and 4.0 was similar in rate but a little more rapid than that at pH 6.8. The coated tablets were administered to three healthy male volunteers and their saliva profiles of TP were compared with those from the commercial sustained release TP tablets such as Slobid and Asconthin. Saliva TP concentrations from the coated tablets were successfully sustained over 48 hours after the dosing and were comparable to those of the commercial sustained-release tablets. The membrane-coating technique is very simple and does not need any sophisticated equipments. In this respect, the membrane-coated tablets may be superior to the commercial sustained-release tablets and this technique is worth adopting by the pharmaceutical industries.
효소 소화성 하이드로겔 정제의 팽윤 및 프록시필린 방출 특성
심창구(Chang Koo Shim),이영미(Young Mee Lee),여소현(So Hyeon Yeo) 대한약학회 1992 약학회지 Vol.36 No.3
Although oral route is the most convenient route for drug administration, the short and variable transit of drug through GI tract restricts the sustained drug absorption after oral administration. Thus, for sustained absorption of drugs, it is desirable to prolong the GI transit time by retaining the dosage forms in the stomach. In this study, the enzyme-digestible swelling hydrogel was synthesized by heating the mixed solution of N-vinyl-2-pyrrolidone[monomerl, acrylated albumin[crosslinking agent] and proxyphylline[drug] at 65oC for 10 hours in the cylindrical test tube. The resultant hydrogel tablet (diameter; 0.77cm, thickness; 0.47cm) was designed to swell in the gastric fluid after oral administration to such a size that passing through the pylorus could be inhibited during the drug release. After releasing drug, the hydrogel was expected to be degraded by pepsin, an enzyme in the stomach, and eventually solubilized. Actually, the hydrogel synthesized in the study swelled to a size larger than the diameter of the pylorus (1.3 +/- 0.7cm) and slowly digested in the presence of pepsin. Drug release from the hydrogel was prolonged up to about 12 hours. The swelling kinetics was dependent on albumin acrylation time, drug content and gel thickness. Particularly the gel thickness was the most important factor that influences on drug release. By adjusting these factors, the albumin-crosslinked hydrogel was expected to be retained in the stomach for up to 60 hours and used as a potential platform of drugs for long-term GI absorption.
심창구(Chang-Koo Shim),김진웅(Jinwoong Kim) 大韓藥學會 2015 약학회지 Vol.59 No.2
The spring convention of the Pharmaceutical Society of Korea (PSK), composed of eight symposia and two special symposia, was held at the K Seoul Hotel on April 17th and 18th in 2014. During the convention, the board meeting of PSK officially approved the birth of Pharmacy History (PH) Division as one of 19 divisions of PSK on April 17th. In the morning of April 18th, an inaugural symposium of PH division was held at the hotel with a theme of "History of Pharmacy in Korea”. In this article, the establishment of PH division, content of the 1st symposium will be described. The future vision of PH division, which will be focused on the study of modern history rather than that of old history, will be described as well. The introduction of modern pharmacy education system to Korea and various events that happened during the establishment of the system may represent issues that should be investigated with the highest priority by the PH division.
Pharmacokinetic Study of Recombinant Human Interferon Alpha A in Rats
심창구,김대덕,김현수,정인환,유무영,Shim, Chang-Koo,Kim, Dae-Duk,Kim, Hyun-Su,Jung, In-Whoan,Yoo, Moo-Young Korean Society for Biochemistry and Molecular Biol 1987 한국생화학회지 Vol.20 No.2
Recombinant human interferon-${\alpha}A$ (인터페론)를 rat에 정맥주사한 다음의 혈청 및 뇨중 인터페론 역가를 정량하여 약물체내속도론을 이용하여 해석하였다. 정맥주사시 2가지 $9.0{\times}10^6\;IU/ml$ 및 $3.6{\times}10^7\;IU/ml$)로 다른 용량을 투여하여 보았으나 용량에 따른 속도론 파라메타의 유의성있는 차이 (p>0.05)가 나타나지 않았다. 이로부터 이정도의 용량에서는 체내동태에 용량의존성 (포화과정)이 나타나지 않는 것으로 생각되었다. 이 인터페론의 체내동태는 저자 등이 이미 보고한 바 있는 Namalva 인터페론의 체내동태와 유사하였으나 문헌에 있는 베타인터페론과는 상이하였다. 이 인터페론의 뇨중 배설속도와 혈중농도의 상관관계가 직선성을 보이는 점으로부터 비록 인터페론이 신장에서 여파, 분비, 재흡수 및 분해, 대사라는 복잡한 과정을 거쳐 뇨중에 배설된다. 하지만 이 연구에서와 같은 혈중농도 범위내에서는 각 과정에 포화현상이 나타나지 않았다는 (또는 나타나도 무시할 수 있는 정도라는) 사실을 알 수 있었다. 신클리어란스($CL_r$)가 전신클리어란스($CL_s$)의 0.1%에 불과한 것은 인터페론이 신장에서 상당량 catabolism을 받기 때문이라고 생각된다. Pharmacokinetic behavior of recombinant human interferon alpha rIFN-${\alpha}A$ was studied in the rat. Serum concentrations of rIFN-${\alpha}A$ after intravenous administration could be explained by two - compartment open model. Pharmacokinetic parameters of f recombinant human interferon alpha administered intravenously at two different doses $9.0{\times}10^6$ and $3.6{\times}10^7\;IU/kg$) were calculated by fitting the observed data to the nonlinear least square program. There were no significant differences in pharmacokinetic parameters such as systemic clearance (CLs), apparent distribution volume at steady state ($Vd_{ss}$), biological half life ($t_{1/2}$) etc. between the two doses. There were also no significant differences between pharmacokinetic parameters of this rIFN-${\alpha}A$ and those of Namalva rIFN-$\alpha$ which were reported previously by us. rIFN-${\alpha}A$ aministered intraveneously had a small distribution volume, which indicates its poor distribution to peripheral or poorly-perfused organs. Renal excretion which might be a sum of filtration, secretion, reabsorption or catabolism in the kidney didn't show any saturation phenomena in the serum concentration range studied $1{\times}10^3-5{\times}10^4\;IU/ml$). Renal clearance accounted less than 0.1% of systemic clearance of rIFN-${\alpha}A$.